Related Experiment Video
Updated: Jan 10, 2026

Investigating Migraine-Like Behavior Using Light Aversion in Mice
Published on: August 11, 2021
CGRP and Migraine: Real-World Insights and Future Therapeutic Directions
Andrew F Russo1,2, Eric A Kaiser3
1Department of Molecular Physiology and Biophysics and Department of Neurology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
Abstract:
Therapeutic targeting of the neuropeptide calcitonin gene-related peptide (CGRP) is a bench-to-bedside success story that has established migraine as a treatable neurological disorder. There are now eight monoclonal antibodies and small-molecule receptor antagonists approved by the US Food and Drug Administration for the acute and preventive treatment of migraine. This review focuses on evolving real-world data for these inhibitors of CGRP activity. While the drugs have been remarkably safe so far, some adverse effects are arising. To conclude, we speculate on the emerging use of CGRP inhibitors for other disorders and what lies on the horizon for combinatorial and neuropeptide-based treatments inspired by the CGRP story.
Related Concept Videos
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Analgesia and Pain Management
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Transducer Mechanism: G Protein–Coupled Receptors
GPCRs are also called heptahelical,...
Direct-Acting Cholinergic Agonists: Pharmacological Actions

